Replies to post #4740 on Biotech Values

[DewDiligence]

>> The fact that the FDA granted fast-track to squalamine goes counter to the idea that side-effects worries them much, however. I recall that a number of specialists had argued fast-track would not be possible for an anti-angiogenesis in AMD. <<

I think you are confusing Fast Track and Accelerated Approval. It is the latter that is unavailable to drugs in AMD. Please refer to #msg-4195284.

A Fast Track designation from the FDA actually says little about a drug per se and a lot about the medical need a drug hopes to serve. Yet it is a widely held misconception that a Fast Track designation has great significance for investors. In #msg-4270492, ‘rstor1’ even suggests shorting companies when they announce receipt of Fast Track status --a strategy that will probably work quite well on balance. Regards, Dew